Implant-associated anaplastic large cell lymphoma (literature review)
Summary. In recent years, there is increasing evidence that breast implants, in rare cases, may be associated with the development of anaplastic large-cell lymphoma (ALCL). According to the literature, the incidence rate of primary anaplastic large cell lymphoma (BIA-ALCL) is estimated at 1 in 30,000 women with textured breast implants. BIA-ALCL occurs in the implant bed after breast reconstruction in women with breast cancer or augmentation. Histologically confirmed BIA-ALCL requires individual treatment by a multidisciplinary team of a clinical oncologist, oncological surgeon, plastic surgeon and hematologist. Treatment BIA-ALCL gives a much better prognosis than at systemic ALCL. Moreover, BIA-ALCL, limited by capsule, has favorable forecast after surgical capsulectomy, even without adjuvant chemotherapy or radiotherapy. However, some patients develop an infiltrative disease with a potentially life-threatening clinical course.
No Comments » Add your